Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022

Upgrades

• According to Summit Insights Group, the prior rating for Applied Materials Inc AMAT was changed from Hold to Buy. For the fourth quarter, Applied Materials had an EPS of $2.03, compared to year-ago quarter EPS of $1.94. The stock has a 52-week-high of $167.06 and a 52-week-low of $71.12. At the end of the last trading period, Applied Materials closed at $104.45.
• JP Morgan upgraded the previous rating for Walgreens Boots Alliance Inc WBA from Neutral to Overweight. For the fourth quarter, Walgreens Boots Alliance had an EPS of $0.80, compared to year-ago quarter EPS of $1.17. At the moment, the stock has a 52-week-high of $55.00 and a 52-week-low of $30.39. Walgreens Boots Alliance closed at $40.13 at the end of the last trading period.
• For Ross Stores Inc ROST, Gordon Haskett upgraded the previous rating of Hold to Buy. In the third quarter, Ross Stores showed an EPS of $1.00, compared to $1.09 from the year-ago quarter. The stock has a 52-week-high of $115.22 and a 52-week-low of $69.24. At the end of the last trading period, Ross Stores closed at $97.93.
• According to Northcoast Research, the prior rating for Domino's Pizza Inc DPZ was changed from Neutral to Buy. Domino's Pizza earned $2.79 in the third quarter, compared to $3.24 in the year-ago quarter. At the moment, the stock has a 52-week-high of $564.73 and a 52-week-low of $299.41. Domino's Pizza closed at $366.73 at the end of the last trading period.
• According to UBS, the prior rating for Conagra Brands Inc CAG was changed from Neutral to Buy. For the first quarter, Conagra Brands had an EPS of $0.57, compared to year-ago quarter EPS of $0.50. The stock has a 52-week-high of $36.97 and a 52-week-low of $30.06. At the end of the last trading period, Conagra Brands closed at $34.94.

See all analyst ratings upgrades.

Downgrades

• For RH RH, Wedbush downgraded the previous rating of Outperform to Neutral. In the second quarter, RH showed an EPS of $8.08, compared to $8.48 from the year-ago quarter. At the moment, the stock has a 52-week-high of $556.59 and a 52-week-low of $207.37. RH closed at $288.50 at the end of the last trading period.
• According to B of A Securities, the prior rating for Coinbase Global Inc COIN was changed from Buy to Neutral. For the third quarter, Coinbase Global had an EPS of $2.43, compared to year-ago quarter EPS of $1.62. At the moment, the stock has a 52-week-high of $258.81 and a 52-week-low of $40.83. Coinbase Global closed at $48.79 at the end of the last trading period.
• For HP Inc HPQ, Credit Suisse downgraded the previous rating of Outperform to Neutral. In the third quarter, HP showed an EPS of $1.04, compared to $1.00 from the year-ago quarter. The current stock performance of HP shows a 52-week-high of $41.47 and a 52-week-low of $24.07. Moreover, at the end of the last trading period, the closing price was at $29.43.
• According to Morgan Stanley, the prior rating for Rent the Runway Inc RENT was changed from Overweight to Equal-Weight. In the second quarter, Rent the Runway showed an EPS of $0.53, compared to $3.75 from the year-ago quarter. At the moment, the stock has a 52-week-high of $8.51 and a 52-week-low of $1.37. Rent the Runway closed at $1.44 at the end of the last trading period.
• Piper Sandler downgraded the previous rating for Chart Industries Inc GTLS from Overweight to Neutral. Chart Industries earned $1.49 in the third quarter, compared to $0.88 in the year-ago quarter. The current stock performance of Chart Industries shows a 52-week-high of $242.59 and a 52-week-low of $108.29. Moreover, at the end of the last trading period, the closing price was at $122.53.
• Piper Sandler downgraded the previous rating for OncoCyte Corp OCX from Overweight to Neutral. At the moment, the stock has a 52-week-high of $2.26 and a 52-week-low of $0.35. OncoCyte closed at $0.43 at the end of the last trading period.
• For Editas Medicine Inc EDIT, Oppenheimer downgraded the previous rating of Outperform to Perform. In the third quarter, Editas Medicine showed an EPS of $0.81, compared to $0.57 from the year-ago quarter. The current stock performance of Editas Medicine shows a 52-week-high of $27.99 and a 52-week-low of $9.59. Moreover, at the end of the last trading period, the closing price was at $11.01.
• For SAP SE SAP, Jefferies downgraded the previous rating of Buy to Underperform. For the third quarter, SAP had an EPS of $1.13, compared to year-ago quarter EPS of $2.05. The current stock performance of SAP shows a 52-week-high of $141.69 and a 52-week-low of $78.22. Moreover, at the end of the last trading period, the closing price was at $111.82.
• Credit Suisse downgraded the previous rating for Editas Medicine Inc EDIT from Outperform to Neutral. In the third quarter, Editas Medicine showed an EPS of $0.81, compared to $0.57 from the year-ago quarter. The stock has a 52-week-high of $27.99 and a 52-week-low of $9.59. At the end of the last trading period, Editas Medicine closed at $11.01.

See all analyst ratings downgrades.

Initiations

• B of A Securities initiated coverage on Insmed Inc INSM with a Buy rating. The price target for Insmed is set to $39.00. Insmed earned $1.09 in the third quarter, compared to $0.96 in the year-ago quarter. The current stock performance of Insmed shows a 52-week-high of $28.94 and a 52-week-low of $16.41. Moreover, at the end of the last trading period, the closing price was at $18.53.
• With an Outperform rating, Raymond James initiated coverage on Fulgent Genetics Inc FLGT. The price target seems to have been set at $45.00 for Fulgent Genetics. In the third quarter, Fulgent Genetics showed an EPS of $0.32, compared to $4.05 from the year-ago quarter. At the moment, the stock has a 52-week-high of $101.98 and a 52-week-low of $31.07. Fulgent Genetics closed at $35.89 at the end of the last trading period.
• HC Wainwright & Co. initiated coverage on 4D Molecular Therapeutics Inc FDMT with a Buy rating. The price target for 4D Molecular Therapeutics is set to $36.00. In the third quarter, 4D Molecular Therapeutics showed an EPS of $0.79, compared to $0.82 from the year-ago quarter. The stock has a 52-week-high of $24.38 and a 52-week-low of $5.32. At the end of the last trading period, 4D Molecular Therapeutics closed at $22.40.
• Piper Sandler initiated coverage on DraftKings Inc DKNG with an Overweight rating. The price target for DraftKings is set to $21.00. In the third quarter, DraftKings showed an EPS of $1.00, compared to $1.35 from the year-ago quarter. The stock has a 52-week-high of $28.55 and a 52-week-low of $9.77. At the end of the last trading period, DraftKings closed at $14.90.
• With an Outperform rating, Credit Suisse initiated coverage on Eli Lilly and Co LLY. The price target seems to have been set at $395.00 for Eli Lilly. Eli Lilly earned $1.98 in the third quarter, compared to $1.77 in the year-ago quarter. The stock has a 52-week-high of $369.80 and a 52-week-low of $231.87. At the end of the last trading period, Eli Lilly closed at $360.77.
• With a Neutral rating, Credit Suisse initiated coverage on Johnson & Johnson JNJ. The price target seems to have been set at $170.00 for Johnson & Johnson. For the third quarter, Johnson & Johnson had an EPS of $2.55, compared to year-ago quarter EPS of $2.60. The current stock performance of Johnson & Johnson shows a 52-week-high of $186.69 and a 52-week-low of $155.72. Moreover, at the end of the last trading period, the closing price was at $174.86.
• Credit Suisse initiated coverage on Pfizer Inc PFE with an Outperform rating. The price target for Pfizer is set to $55.00. In the third quarter, Pfizer showed an EPS of $1.78, compared to $1.34 from the year-ago quarter. The stock has a 52-week-high of $58.55 and a 52-week-low of $41.45. At the end of the last trading period, Pfizer closed at $48.33.
• Credit Suisse initiated coverage on AbbVie Inc ABBV with an Outperform rating. The price target for AbbVie is set to $170.00. For the third quarter, AbbVie had an EPS of $3.66, compared to year-ago quarter EPS of $2.83. The stock has a 52-week-high of $175.91 and a 52-week-low of $128.26. At the end of the last trading period, AbbVie closed at $152.16.
• With a Neutral rating, Credit Suisse initiated coverage on Bristol-Myers Squibb Co BMY. The price target seems to have been set at $78.00 for Bristol-Myers Squibb. In the third quarter, Bristol-Myers Squibb showed an EPS of $1.99, compared to $2.00 from the year-ago quarter. The current stock performance of Bristol-Myers Squibb shows a 52-week-high of $81.17 and a 52-week-low of $60.86. Moreover, at the end of the last trading period, the closing price was at $77.16.
• With an Underperform rating, Credit Suisse initiated coverage on Amgen Inc AMGN. The price target seems to have been set at $240.00 for Amgen. Amgen earned $4.70 in the third quarter, compared to $4.67 in the year-ago quarter. The stock has a 52-week-high of $296.67 and a 52-week-low of $214.39. At the end of the last trading period, Amgen closed at $287.30.
• With an Outperform rating, Credit Suisse initiated coverage on Merck & Co Inc MRK. The price target seems to have been set at $120.00 for Merck & Co. For the third quarter, Merck & Co had an EPS of $1.85, compared to year-ago quarter EPS of $1.78. At the moment, the stock has a 52-week-high of $103.76 and a 52-week-low of $72.88. Merck & Co closed at $102.31 at the end of the last trading period.

See all analyst ratings initiations.